An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus - ADDRESS+

Aoyama Yumi0 个研究点目标入组 12 人开始时间: 2021年8月27日最近更新: 2024年5月27日

试验速览

暂无简介。

•Participants are eligible to be included in the trial only if all of the following criteria apply:
•1. Ability to understand the requirements of the trial, to provide written informed consent (including consent
•for the use and disclosure of research-related health information), willingness and ability to comply with the
•trial protocol procedures (including required trial visits).
•2. The participant participated in trial ARGX-113-1904 and completed the study or has the defined criteria for rollover.
•3. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating clinical trials and:
•a. Male participants:
•- Male participants must agree to use acceptable method of contraception, and not donate sperm from signing the ICF until the end of the study.
•b. Female participants:
•- Women of childbearing potential must:
•- have a negative serum pregnancy test at screening and negative urine pregnancy test at baseline
•before the IMP can be administered.
•- agree to use a highly effective or acceptable contraception methods, which should be maintained at
•minimum until 90 days after the last dose of IMP.

•Participants are excluded from the trial if any of the following criteria apply:
•1. Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after the last administration of IMP.
•2. Participants with clinical evidence of other significant serious disease or participants who recently underwent or have planned a major surgery during the period of the trial, or any other condition in the opinion of the investigator, that could confound the results of the trial or put the participant at undue risk.
•3. Known hypersensitivity to any of the components of the administered treatments.

发起方

Aoyama Yumi